Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth Medicare PPO Formulary Coverage Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAmeriHealthPolicy FID 00026201

    AmeriHealth Medicare PPO 2026 Formulary (Drug List)

    Customize your policy alerts

    Sign up for AmeriHealth Policy FID 00026201 alerts

    Get alerted when Policy FID 00026201 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the AmeriHealth Medicare PPO 2026 formulary (Drug List) describing covered prescription drugs, coverage rules, restrictions (e.g., prior authorization, step therapy, quantity limits), and how members can request exceptions. It applies to AmeriHealth Medicare PPO members and their prescribers/pharmacies.

    Policy Summary
    PayerAmeriHealth
    PolicyAmeriHealth Medicare PPO 2026 Formulary (Drug List)
    Policy CodePolicy FID 00026201
    Change TypeAnnual formulary update (no material changes noted)
    Effective Date4/21/2026
    Last ReviewApr 21, 2026
    Next Review DateApr 21, 2026
    Key ActionObtain prior authorization from AmeriHealth Medicare PPO before dispensing drugs marked PA to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    monthlyupdates posted
    30 daysmember notice
    72 hoursstandard exception timeframe
    24 hoursexpedited exception timeframe
    60 daystemporary supply notice
    4/21/2026document date

    Coverage Criteria and Formulary Rules

    General coverage conditions

    Covered when plan rules and any specific drug requirements/limits are met.

    Formulary coverage general: Drug is on AmeriHealth Medicare PPO formulary AND prescription is filled at a plan network pharmacy

    From formulary overview; see formulary table for product-specific tier and flags.

    Utilization controls: Any product-specific requirements shown in the formulary (e.g., PA, QL, ST, NF) are met prior to claim adjudication

    Prior authorization must be obtained where 'PA' is indicated; quantity requests must not exceed listed QL.

    Documentation and authorization: When PA or overrides are required, prescriber must submit supporting clinical rationale and authorization details as directed by the plan

    See prior authorization and documentation requirements; failure to obtain PA may result in noncoverage.

    Policy Summary
    PayerAmeriHealth
    PolicyAmeriHealth Medicare PPO 2026 Formulary (Drug List)
    Policy CodePolicy FID 00026201
    Change TypeAnnual formulary update (no material changes noted)
    Effective Date4/21/2026
    Last ReviewApr 21, 2026
    Next Review DateApr 21, 2026
    Key ActionObtain prior authorization from AmeriHealth Medicare PPO before dispensing drugs marked PA to avoid claim denial.
    SourceLink
    On This Page
    Coverage Criteria and Formulary RulesCoding, Status Codes, and Quantity ExamplesProvider Requirements, Prior Authorization, Step Therapy, and DocumentationFormulary Background and ScopeFormulary Legend and DefinitionsStep Therapy Rules and Affected ProductsQuantity Limits by Product (Selected Examples)

    Temporary supply / Transition fills

    Temporary coverage during membership transitions or while an exception is requested.

    New or continuing member transition supply: For each drug not on formulary or with a coverage restriction, the plan will provide a temporary 30-day supply while member and prescriber pursue an exception or alternative30-day supply

    Applies during the first 90 days of membership; refills allowed up to 30-day maximum per prescription.

    Long-term care emergency supply: For long-term care residents beyond the first 90 days, the plan will cover a 31-day emergency supply while a formulary exception is pursued31-day supply

    Pharmacy may notify the plan of setting changes to ensure uninterrupted access.

    Limit if coverage denied: If a formulary exception is not approved after the temporary supply, subsequent fills will not be paid by the plan

    Temporary supply is contingent on pursuing exception or switching to a formulary alternative.

    Formulary tier and modifier entries

    Formulary coverage is indicated by tier and may include PA or QL requirements; individual coverage is determined per listed product.

    Per-product tier and flags: Each product entry lists a tier and may include one or more modifiers (PA = prior authorization required; QL = quantity limit; ST = step therapy; NF = not formulary) that alter coverage conditions

    Providers must consult the specific product line entry for exact tier, PA, QL, ST, or NF status and applicable limits.

    Quantity limits enforcement: When a product shows a QL, the plan will limit the covered amount to the listed units per time period (e.g., QL (1 EA per 252 days), QL (0.5 ML per 999 days))As listed per product

    Dispensing beyond listed QL requires documentation and prior authorization/override.

    Not-formulary (NF) entries: Products marked NF are not covered on the formulary and require a formulary exception request for consideration of coverage

    Refer to the formulary legend (page 6) and exception process.

    The formulary uses the designation Non-Formulary (NF) to indicate that a drug is not covered under the plan. When an entry is marked NF, coverage is not provided unless a Formulary Exception is requested and approved. The Requirements/Limits column on each product line describes these statuses and any additional controls (e.g., PA, QL) that modify coverage. Providers or members seeking coverage for an NF medication must follow the plan's exception request process and provide supporting clinical information for review.

    Multiple formulary entries in the listing are labeled NF, which in this document denotes non-formulary status or a special formulary designation. Items shown as NF are typically not covered as a standard benefit and will require an exception request or other plan-specific handling to be considered for coverage. Consult the table legend (referenced on page 6) for the plan's exact symbol meanings.

    Some products in the extract are explicitly marked NF or have coverage fields that do not list a tier or utilization flag, indicating either a non-formulary designation or an unspecified coverage status in the provided segments. Where PA or QL are not shown, the absence of a tier does not imply automatic coverage; providers should confirm plan rules or submit an exception when required.

    Within the supplied formulary excerpts there are no discrete clinical exclusion statements; the listing is limited to formulary placement and utilization control markers such as tier, PA, QL, ST, or NF. Clinical exclusion logic (e.g., specific diagnoses or clinical contraindications) is not provided in these chunks and must be inferred from the requirements/limits or obtained from other policy sections.

    Products labeled NF are not on the formulary and therefore are not covered under the plan's standard benefit in this extract. Such items may be excluded from coverage or require a formulary exception or other special handling; the formulary references the legend (page 6) for the plan-specific interpretation of NF and related symbols.

    Drugs marked NF in the table indicate non-formulary status in the listing and may require plan-specific prior authorization or an exception process to be considered for coverage. Providers should reference the formulary legend and submit required documentation when requesting coverage for NF items.

    The segments provided do not contain explicit statements that any item is not medically necessary. The formulary rows are limited to tier and utilization flags (e.g., PA, QL, NF, ST); determinations of medical necessity or non-medical necessity are not present in these fragments.

    No explicit not medically necessary determinations are shown in the supplied excerpts. Where utilization controls (PA, QL, ST, NF) appear, they reflect coverage requirements or limits rather than formal medical necessity denials within these chunks.

    Coding, Status Codes, and Quantity Examples

    Quantity limits shown in formularymixed
    QL (60 EA per 30 days)Quantity limit specified for multiple oral/injectable products (example text from entries)
    QL (56 EA per 28 days)Quantity limit for linezolid oral tablet
    Prior authorization indicatorsmixed
    PAPrior authorization indicator shown in Requirements/Limits for some antifungal entries
    Formulary items (no CPT/HCPCS/ICD-10 codes)mixed
    noneNo procedure, diagnosis, or billing codes listed in this excerpt — only drug names and formulary flags.
    Formulation identifiers / NDA referencesmixed
    nda020503albuterol sulfate HFA inhalation aerosol solution (reference listed in formulary)
    nda020983albuterol sulfate HFA inhalation aerosol solution (alternate NDA reference listed)
    Formulary quantity limits (examples)mixed
    QL (148 EA per 365 days)Quantity limit for ELIQUIS DVT/PE STARTER PACK ORAL TABLET
    QL (60 EA per 30 days)Quantity limit for ELIQUIS ORAL TABLET 2.5 MG
    QL (90 EA per 30 days)Quantity limit for ELIQUIS ORAL TABLET 5 MG
    Formulary status codesmixed
    PAPrior authorization required (as marked for many nebulizer and other formulations)
    NFNot Formulary / not covered on formulary listing
    inv-19: Quantity limit examples — 60 EA per 30 days; 56 EA per 28 days
    Example QL — 60 EA/30 daysObserved as a common quantity limit for doxycycline, erythromycin, fidaxomicin and other entries (QL 60 EA per 30 days)
    Example QL — 56 EA/28 daysListed for linezolid oral tablet (QL 56 EA per 28 days)
    ContextQuantity limits appear in the Requirements/Limits column and apply per specified period (e.g., per 30 days or per 28 days)
    inv-20: Quantity limits examples — QL examples observed: 30 EA per 30 days, 84 EA per 365 days, 168 EA per 365 days, 360 EA per 30 days
    QL — 30 EA per 30 daysApplied to multiple antiviral combination products (e.g., BIKTARVY, COMPLERA, DESCOVY) as QL (30 EA per 30 days)
    QL — 84 EA per 365 daysEPCLUSA oral packet/tablet entries include PA; QL (84 EA per 365 days)
    QL — 168 EA per 365 daysEPCLUSA oral packet/tablet entries also show QL (168 EA per 365 days) for other presentations
    QL — 360 EA per 30 daysListed for certain antiviral formulations (e.g., lopinavir-ritonavir, MAVYRET) as QL (360 EA per 30 days)
    inv-21: Examples of quantity limits — Exact QL entries (e.g., INCRUSE ELLIPTA QL 30 EA per 30 days; SPIRIVA QL 30 EA per 30 days; fluticasone-salmeterol QL 60...)
    INCRUSE ELLIPTAQL (30 EA per 30 days) — INCRUSE ELLIPTA inhalation aerosol powder 62.5 MCG/ACT listed with QL 30 EA per 30 days
    SPIRIVA HANDIHALERQL (30 EA per 30 days) — SPIRIVA HANDIHALER inhalation capsule entry shows QL 30 EA per 30 days
    fluticasone-salmeterolQL (60 EA per 30 days) — fluticasone-salmeterol breath-activated inhalation powder shows QL 60 EA per 30 days
    inv-22: Examples of QL thresholds — 8 GM/30 days; 60 EA/30 days; 2 EA/30 days; 360 EA/30 days; 2.4 ML/28 days; 600 ML/30 days
    8 GM per 30 daysCOMBIVENT RESPIMAT inhalation aerosol solution listed with QL (8 GM per 30 days)
    60 EA per 30 daysfluticasone-salmeterol breath-activated forms listed with QL (60 EA per 30 days)
    2 EA per 30 daysSome injection/packaged presentations show low EA limits (examples include certain therapy-pack entries listed elsewhere)
    360 EA per 30 daysEltrombopag and some antiviral/antiretroviral formulations show QL up to 360 EA per 30 days
    2.4 ML per 28 daysINVEGA HAFYERA prefilled syringe entry shows QL (3.5 ML or 5 ML per 180 days) and related syringe ML-level QLs (e.g., 2.4 mL referenced in vaccine/IM entries)
    600 ML per 30 daysMEKINIST oral solution and other oral solution entries include ML-based QLs (examples include 1200 ML per 30 days; XARELTO oral suspension 600 ML per 30 days)
    inv-23: Quantity limits examples — QL (30 EA per 30 days; 45 EA per 30 days; 60 EA per 30 days; 2 mL per 28 days; 3 mL per 28 days)
    30 EA per 30 daysCommon tablet QL observed for statins and other oral tablets (e.g., lovastatin QL 30 EA per 30 days)
    45 EA per 30 daysSimvastatin 10/20/5 mg entries include QL (45 EA per 30 days) for certain strengths
    60 EA per 30 daysMultiple cardiovascular agents (e.g., sacubitril-valsartan, valsartan-HCTZ combinations) show QL (60 EA per 30 days)
    2 mL per 28 daysSome injectable/auto-injector presentations (e.g., EMGALITY/other mL-based products) use mL per 28-day limits
    3 mL per 28 daysREPATHA and PRALUENT-type biologic presentations are listed with mL-based QLs (e.g., REPATHA QL 3 mL per 28 days)
    inv-24: Quantity limits examples — Examples include QL (90 EA/30 days), QL (180 EA/30 days), QL (240 EA/30 days), QL (480 ML/30 days), QL (60 EA/30 days)
    90 EA per 30 daysELIQUIS and multiple oral tablet products show QL (90 EA per 30 days) for certain strengths
    180 EA per 30 daysSome oncology or specialty tablet strengths and certain opioid combinations are limited to QL (180 EA per 30 days)
    240 EA per 30 days / 480 ML per 30 daysOral tablet and solution limits include QL (240 EA per 30 days) for LONSURF and QL (480 ML per 30 days) for select liquid formulations
    60 EA per 30 daysRepeated cardiac and other chronic therapy entries show QL (60 EA per 30 days) as a common monthly limit
    inv-25: Quantity limits examples — Examples include 32 EA/30 days; 8 EA/30 days; 540 ML/30 days
    32 EA per 30 daysSumatriptan nasal solution 5 mg/act listed with QL (32 EA per 30 days)
    8 EA per 30 daysSome triptan presentations (e.g., sumatriptan nasal 20 mg/act or subcutaneous injectors) show QL (8 EA per 30 days)
    540 ML per 30 daysSodium oxybate oral solution is listed with QL (540 ML per 30 days)

    Provider Requirements, Prior Authorization, Step Therapy, and Documentation

    Prior Authorization

    Prior Authorization Required

    AmeriHealth Medicare PPO requires prior authorization (PA) for many drugs listed in the formulary. Prescribers or members must obtain approval from AmeriHealth Medicare PPO before dispensing PA‑designated drugs; claims may be denied or not covered if PA is not obtained.

    • Applies to drugs marked 'PA' in the formulary Requirements/Limits column.
    • Failure to obtain PA may result in claim denial or non‑coverage.
    Prior Authorization

    Prior Authorization for Select Antifungals

    Certain antifungal agents and formulations in the formulary are designated PA. Prescribers should check the Requirements/Limits column for PA flags (examples in the antifungals section include amphotericin B liposome, CRESEMBA, posaconazole delayed‑release tablets). Obtain PA prior to dispensing these antifungals.

    • Examples: amphotericin B (PA), CRESEMBA (PA), posaconazole oral tablet delayed release (PA).
    • Check formulary entries for the 'PA' symbol and follow PA process before fill.
    Prior Authorization

    Prior Authorization Required for PA‑Marked Drugs

    Any drug in the formulary marked 'PA' requires prior authorization before the plan will cover it. This includes many specialty, oncology, antiviral, CNS, and other agents. Verify PA status at claim adjudication and submit required documentation.

    • 'PA' appears across multiple drug classes — verify per‑product requirements before dispensing.
    • PA applies to both brand and generic products when indicated in the Requirements/Limits column.
    Prior Authorization

    Prior Authorization for Specialty/Oncology Drugs

    Many specialty and oncology agents are subject to PA and often also to quantity limits. Prescribers must obtain PA for these agents and include clinical rationale supporting the requested therapy.

    • Examples: numerous oral oncology therapy packs and specialty oral agents marked 'PA' (see formulary oncology sections).
    • Quantity limits (QL) frequently accompany PA for oncology agents — document dosing and duration in PA submission.
    Prior Authorization

    Prior Authorization Required for Some Listed Products

    Some listed products across the formulary (vaccines, specialty injectables, lipid agents, CNS agents, etc.) are designated 'PA' — obtain PA before claim submission to avoid denials.

    • Examples: certain vaccines (e.g., ENGERIX‑B) show PA; select lipid agents and specialty injectables show PA with QL.
    • Follow plan PA process for listed products prior to dispensing.
    Prior Authorization

    Prior Authorization Required for Select Agents

    Select agents such as specialty lipid therapies and other high‑cost drugs are subject to prior authorization and quantity limits. Providers should confirm PA and QL when prescribing these agents.

    • Examples: REPATHA, PRALUENT and similar agents are marked PA with specified QL.
    • Include clinical justification and prior therapy history when requesting PA.
    Prior Authorization

    Prior Authorization Indicated for Some Agents

    Certain stimulant, wakefulness, and other agents are indicated as requiring PA in the formulary. Confirm PA requirements and submit supporting medical documentation as part of the authorization request.

    • Examples include modafinil/armodafinil entries with PA and QL.
    • Prescribers should document prior therapies and diagnosis to support PA.
    Prior Authorization

    Prior Authorization Required for Some Drugs

    Some drugs (e.g., UBRELVY, sodium oxybate, others) are listed with PA and accompanying quantity limits; an approved PA is required to avoid claim denial.

    • UBRELVY: PA; QL example provided in formulary.
    • Sodium oxybate: PA with QL (540 mL per 30 days).
    Prior Authorization

    Prior Authorization Required for Select Drugs

    Select branded products are specifically marked 'PA' in the formulary and require authorization prior to coverage. Verify PA status for these products at point of prescribing or claims submission.

    • Examples: LYBALVI, NUPLAZID show PA with QL in entries.
    • Confirm PA and obtain authorization number when approved.
    Denial Risk

    PA and QL May Trigger Denials

    The formulary uses PA, QL, ST and NF flags. PA and QL flags may trigger claim denials if requirements are not met; providers must follow the flags and submit authorization requests with necessary documentation.

    • PA and QL without an approved authorization can result in denial or non‑coverage.
    • ST (step therapy) flags may require trials of preferred agents before coverage of non‑preferred agents.
    Prior Authorization

    Prior Authorization Indicated on Many Specialty Drugs

    Prior authorization is indicated for many specialty drugs listed throughout the formulary; these frequently include oncology, hematology, rare disease and similar high‑cost therapies. Obtain PA prior to dispensing to prevent denials.

    • Numerous specialty agents are labeled 'PA' across the oncology and specialty sections.
    • PA requests should include diagnosis, prior treatments, and rationale for the requested agent.
    Prior Authorization

    Prior Authorization Triggers for Selected Vaccines

    Some vaccines and vaccine formulations are designated PA in the formulary. Verify PA for specific vaccine presentations (e.g., certain formulations of ENGERIX‑B) before administration or billing.

    • Check vaccine entries in the formulary Requirements/Limits column for PA flags.
    • Obtain authorization when vaccine product row indicates PA to avoid non‑coverage.
    Denial Risk

    PA and QL May Trigger Denial

    PA flags combined with QL restrictions may lead to denial if the requested quantity exceeds the plan limit or if no PA is on file. Providers should review and adhere to QL values shown in the formulary.

    • Examples: REPATHA QL 3 mL/28 days with PA; sodium oxybate QL 540 mL/30 days with PA.
    • If a requested fill exceeds QL, include supporting clinical justification when requesting an exception.
    Billing Rule

    Quantity Limit Enforcement

    The formulary specifies quantity limits (QL) for many products. Prescribers and pharmacists must observe these limits; dispensing beyond the QL requires PA or an approved exception.

    • Examples shown across multiple sections (e.g., QL 60 EA per 30 days for many products).
    • Quantity limits appear in the Requirements/Limits column per product.
    Documentation Required

    Documentation Required for PA/QL Requests

    When requesting prior authorization or seeking an override of a quantity limit, providers must submit supporting documentation and clinical rationale. Document dosing, duration, prior therapies, and medical necessity in the PA request.

    • Supporting statement from prescriber is required for exception requests; decisions generally within 72 hours (24 hours for expedited).
    • Include prior therapy history and medical rationale when requesting PA/QL exceptions.
    Documentation Required

    Document PA Approvals and Quantity Justification

    Document and retain authorization details (authorization number, approval scope, approved quantity and duration) and include clinical justification for any QL exceptions. This reduces risk of claims denial at adjudication.

    • Include authorization number on claims when required.
    • Supply clinical notes showing need for quantities beyond listed QL when seeking exception.
    Note

    Use of Formulary Flags

    The formulary uses flags (PA, QL, ST, NF, NDS) to indicate utilization controls. Providers must interpret and follow these symbols per the formulary legend (see page 6) when prescribing and billing.

    • PA = Prior Authorization, QL = Quantity Limit, ST = Step Therapy, NF = Non‑Formulary, NDS = Non‑Extended Day Supply.
    • Refer to the formulary legend (page 6) for complete definitions.
    Note

    Use Formulary Legend for Interpretation

    Refer to the formulary legend (page 6) for symbol definitions and interpretation guidance. Follow the flags shown in each product row to determine whether PA, QL, ST or other limits apply.

    • Legend clarifies meanings of PA, QL, ST, NF, NDS.
    • Use the legend to resolve any ambiguity in product entries.
    Documentation Required

    Documentation for PA/QL/ST Items

    For items flagged with PA, QL, or ST, providers should submit the required documentation and clearly indicate the utilized flag in the request. Keep records of approvals to present at claims adjudication if needed.

    • PA/ST/QL items require documentation including diagnosis, prior therapies, and intended dosing.
    • Retain approval documentation and authorization numbers for claim submission.
    Note

    Follow Formulary Flags and Page‑6 Legend

    Follow the plan's formulary flags and the page‑6 legend when determining prior authorization, quantity limits and step therapy applicability. The formulary entries drive coverage decisions at the time of claim adjudication.

    • Coverage determination is contingent on meeting PA/QL/ST requirements shown in each product row.
    • When in doubt, contact AmeriHealth Medicare PPO or consult the online PA/ST guidance referenced in the formulary.
    Documentation Required

    Quantity Limits Documentation

    The formulary contains many explicit quantity limits; providers should document clinical rationale when requesting quantities exceeding those limits. QL values are shown per product in the Requirements/Limits column.

    • Examples include therapy pack and per‑period QL values (e.g., QL 84 EA per 365 days, QL 120 EA per 30 days).
    • Include justification for exceptions when requesting QL increases.
    Step Therapy

    Step Therapy Is Required for Some Drugs

    Step therapy (ST) is required for some drugs and therapy packs indicated in the formulary. Where ST is shown, members may need to try specified preferred drugs first before coverage of the designated agent.

    • Examples: XCOPRI therapy packs and certain psychiatric medication titration packs are marked 'ST'.
    • When ST applies, document trials of preferred agents or submit an exception request with clinical rationale.
    Step Therapy

    Step Therapy Not Explicitly Detailed

    The formulary does not always provide explicit step‑therapy algorithms in this excerpt. Tier placement and flags imply sequencing but detailed step requirements are available in the plan's PA/ST guidance documents.

    • Some entries show tiers and QL but not explicit step sequencing.
    • Consult the plan's online documents or contact AmeriHealth for specific ST criteria.
    Step Therapy

    Possible Step Edits (No Explicit Rules)

    At claims adjudication, step edits may be applied based on tiers, PA and ST flags even if explicit step rules are not printed in the product row. Providers should anticipate possible step edits and submit supporting documentation.

    • Tier placement can imply preference and trigger step edits.
    • If a claim is denied for ST, submit documentation of prior trials or request an exception.
    Step Therapy

    Tier Placement May Imply Step Requirements

    Formulary tier placement can imply preferred agents and may affect step therapy application; higher tier products are more likely to have PA/ST or QL requirements. Review tier and flaging together when prescribing.

    • Tiers indicate cost‑sharing and may reflect preferred sequencing.
    • Use tier + flag information to determine if step therapy likely applies.
    Step Therapy

    Formulary Tiers Imply Preferred Agents

    Formulary tiers identify preferred agents by tier but do not replace explicit step therapy criteria; use the formulary and PA/ST guidance together to determine coverage sequencing.

    • Tiers show preferred agents; ST flags indicate where step therapy applies.
    • When requesting an exception, prescribers must provide supporting medical rationale.
    Step Therapy

    Step Therapy Flagged Items

    Some products are specifically flagged 'ST' in the formulary indicating step therapy applies (examples include SAVELLA, XCOPRI therapy packs, SANCUSO patch, EXXUA, FANAPT, FETZIMA titration packs). Providers must ensure step requirements are met or request an exception.

    • Examples: SAVELLA = ST; XCOPRI therapy packs = ST; SANCUSO TRANSDERMAL PATCH = ST.
    • If ST conditions are not met, submit a step‑therapy exception with prescriber's supporting statement.
    Step Therapy

    Step Therapy Indicated for Some Agents

    Step therapy is indicated for some agents and therapy packs; when ST applies, document prior use of required first‑line agents or request an exception with medical justification.

    • Examples: EXXUA titration pack, FANAPT titration packs, FETZIMA titration pack marked ST.
    • Provide documentation of trials and outcomes to support exceptions.
    Step Therapy

    Step Therapy Applies to Select Products

    Step therapy applies to select branded and therapy‑pack products; follow ST flags when prescribing and advise patients that prior trials of preferred drugs may be required for coverage.

    • ST applies to some titration packs and branded products (listed on their product rows).
    • Contact AmeriHealth or consult the PA/ST guidance for the required prior agents.
    Step Therapy

    Step Therapy Examples

    Examples of products with ST include SANCUSO TRANSDERMAL PATCH, XCOPRI therapy packs, SAVELLA and various titration packs for psychiatric/neurology agents. Confirm ST applicability before dispensing.

    • SANCUSO TRANSDERMAL PATCH = ST; XCOPRI = ST; SAVELLA = ST.
    • When ST applies, ensure required step(s) have been met or submit exception documentation.
    Documentation Required

    Exception Request Supporting Statement Required from Prescriber

    When requesting an exception to PA, ST, or QL, the prescriber must provide a supporting statement explaining the medical necessity. AmeriHealth generally decides within 72 hours of receiving the prescriber's supporting statement (24 hours for expedited requests).

    • Prescriber's supporting statement should explain why alternative/formulary drugs are not appropriate.
    • Expedited exceptions may be requested if waiting could seriously harm the patient.

    Formulary Background and Scope

    The formulary groups drugs by medical condition and provides an alphabetical index for lookup. It also explains drug types (for example, generic drugs, original biological products, and biosimilars) and summarizes the meaning of table annotations such as PA (prior authorization), QL (quantity limit), ST (step therapy), and NF (non-formulary). Providers should consult the referenced legend (page 6) and the formulary index when interpreting product-level requirements.

    Formulary Legend and Definitions

    inv-85: Generic drugs — definition and substitution note
    Definition — Generic drugsFDA‑approved drugs with the same active ingredient as the brand name; usually work similarly and often cost less; may be substituted at the pharmacy per state law
    Substitution noteGeneric drugs usually can be substituted for the brand name drug at the pharmacy without a new prescription, depending on state laws
    ContextFormulary distinguishes brand and generic names; see Evidence of Coverage for further detail
    inv-86: Original biological products and biosimilars — definition and interchangeability note
    Definition — Biologicals & BiosimilarsBiological products are complex drugs; biosimilars are alternatives to original biologics and may be interchangeable depending on state laws
    Interchangeability noteSome biosimilars designated interchangeable may be substituted for the original biological product at the pharmacy per state law
    ContextFormulary treats biologics and biosimilars alongside drugs; substitution follows state rules
    inv-87: Non-formulary or special handling indicator as used in the Requirements/Limits column — NF
    Legend referenceThe formulary notes users can find symbol/abbreviation meanings on page 6 for exact interpretation
    Coverage implicationDrugs marked NF are generally not covered under the plan unless an exception is granted
    inv-88: Quantity limit — QL (e.g., 'QL (60 EA per 30 days)')
    QL — Quantity Limit notationQuantity limit entries are shown as 'QL (e.g., QL (60 EA per 30 days))' in the Requirements/Limits column
    Applies per periodQL specifies the maximum number of units allowed within the stated time period (EA per 30 days, ML per 30 days, etc.)
    Override/documentationDispensing beyond a listed QL requires documentation, PA, or exception as described in formulary guidance
    inv-89: Prior authorization — indicates the drug requires prior approval before coverage (PA)
    Provider actionPrescribers or members must obtain PA prior to dispensing; failure to obtain PA may result in noncoverage or claim denial
    Where shownPA appears in the Requirements/Limits column next to specific products and formulations (see product line entries)
    inv-90: Quantity limit — maximum number of units allowed in the specified period (QL examples)
    QL — Maximum units per periodQuantity Limit (QL) specifies the maximum number of units allowed in the specified period (examples in the formulary include EA per 30 days, ML per 30 days)
    ExamplesDocument provides many QL examples (e.g., 30 EA/30 days; 360 EA/30 days; 1200 ML/30 days) applied per product
    EnforcementClaims exceeding QL may be denied or require an exception/PA per plan rules
    inv-91: No Formulary (Not Formulary) indicator used in this document (legend on page 6)
    Legend — No Formulary (Not Formulary) indicatorFormulary legend (page 6) defines 'NF' and other symbols used throughout the drug list
    Where to find definitionsThe formulary instructs users to consult page 6 for exact meanings of symbols and abbreviations
    ImplicationEntries marked NF indicate the drug is not on the plan's formulary listing in this extract
    inv-92: PA — Prior Authorization flag shown in the formulary
    PA — Prior Authorization indicatorPA flag is shown in the formulary Requirements/Limits column to indicate prior authorization is required for coverage
    Action requiredWhen PA is present, providers must submit an authorization request to AmeriHealth Medicare PPO before the claim will be covered
    ExamplesPA appears for many specialty, antifungal, oncology, and select other drug entries in the formulary
    inv-93: QL — Quantity Limit — maximum allowable quantity per time period
    QL — Quantity Limit definitionQuantity Limit (QL) indicates the maximum allowable quantity per the listed time period (e.g., EA per 30 days or ML per 30 days)
    Form exampleMany entries show QL in the Requirements/Limits column (e.g., QL (360 EA per 30 days), QL (60 EA per 30 days))
    Provider noteProviders should document clinical need when requesting quantities exceeding the listed QL
    inv-94: Tier — Formulary cost-sharing or placement tier (numeric values shown, e.g., 3,4,5 or NF)
    Tier — Formulary placementTier indicates formulary cost‑sharing or placement (numeric tiers shown in the table, e.g., 1–5); 'NF' may replace a numeric tier for non‑formulary items
    InterpretationTier combined with PA/QL/NDS/NF flags modifies coverage and utilization requirements for each drug entry
    ReferenceSpecific tier values and accompanying flags are listed per product line in the formulary
    inv-95: PA — Prior Authorization — coverage requires pre-approval
    PA — Prior authorization requiredPrior authorization requires pre‑approval from the plan before coverage (PA shown in Requirements/Limits)
    ConsequenceFailure to obtain PA may result in noncoverage or denial of the claim
    How to requestProviders should follow the plan's PA submission instructions as described in formulary and plan materials
    inv-96: QL — Quantity Limit — maximum units allowed per specified time period (e.g., EA per 30 days)
    QL — Quantity Limit (examples)Examples shown throughout the formulary include QL values such as QL (30 EA per 30 days), QL (1200 ML per 30 days), QL (240 EA per 30 days)
    NotationQL appears in the Requirements/Limits column and is enforced per the period stated
    Provider actionClaims exceeding QL require documentation, PA, or an approved exception per plan rules
    inv-97: QL — Quantity limit example (e.g., 1 EA per 252 days)
    Example — 1 EA per 252 daysSome vaccine entries use long-period QLs (e.g., ABRYSVO QL 1 EA per 252 days) as shown in the vaccine section
    FormatQL entries can specify unusual periods (per 252 days, per 999 days) for specialty/vaccine products
    Refer to legendExact handling and interpretation of uncommon periods are described in the formulary legend (page 6)
    inv-98: PA — Prior authorization; coverage requires approval before benefit is provided
    PA — Prior authorization (definition)Prior authorization (PA) means coverage requires approval before the drug is filled; providers/prescribers must request PA from the plan
    When usedPA is indicated in the Requirements/Limits column next to affected drug entries (common for specialty, oncology, and select other agents)
    Potential denialClaims submitted without required PA may be denied or not covered by the plan
    inv-99: NF — Formulary designation used in the list (legend on page 6)
    NF — Formulary designation'NF' indicates a drug is not on the plan formulary in this listing and may require a formulary exception request to be considered for coverage
    Legend locationUsers are directed to page 6 for exact meanings of NF and other symbols
    ImplicationNF entries are typically excluded from standard coverage unless an approved exception is obtained
    inv-100: QL — Quantity limit examples (e.g., 60 EA per 30 days)
    QL example — 60 EA per 30 daysMultiple entries (e.g., LENVIMA, REPATHA, sacubitril‑valsartan) show QL (60 EA per 30 days) as a common monthly limit
    QL enforcementQuantity limits are enforced at claims processing; requests above QL need PA or exception justification
    Cross-referenceSee product‑level entries for exact QL units and periods per formulation
    inv-101: PA — Prior authorization required before coverage
    PA — Prior Authorization requiredPrior authorization must be obtained before coverage for drugs marked 'PA' in the formulary
    Provider requirementProviders must submit necessary documentation and obtain authorization number to support coverage
    Denial riskFailure to obtain PA can result in the plan not covering the drug
    inv-102: NDS / NF — NDS indicates non-standard supply; NF indicates non-formulary
    NDS / NF — SymbolsNDS indicates non‑standard supply; NF indicates non‑formulary — meanings further defined in the formulary legend (page 6)
    Where usedThese symbols appear in the Requirements/Limits column to indicate supply or formulary status for specific presentations
    Provider actionConsult the formulary legend and plan policies when NDS or NF is shown to determine coverage/administrative requirements
    inv-103: Quantity Limit (per 30 days) — QL
    QL (per 30 days) — shorthandThe formulary uses 'QL' to denote quantity limits typically expressed per 30 days (e.g., QL (60 EA per 30 days))
    Unit typesUnits used include EA (each) and ML (milliliters) depending on product formulation
    Apply at dispensingPharmacies should enforce QL at point of sale per the specified period
    inv-104: Prior Authorization — PA
    PA — Prior Authorization abbreviationPA denotes Prior Authorization is required for coverage when shown in the Requirements/Limits column
    Obtain prior to fillProviders/prescribers must obtain PA prior to the beneficiary filling the prescription to avoid denial
    DocumentationPA requests should include clinical rationale as described in plan exception procedures
    inv-105: Formulary symbol annotations — see page 6 legend for exact meanings (NDS / NF)
    Formulary legend referenceSee page 6 legend for exact meanings of formulary symbols/annotations such as NDS and NF
    Interpretation guidanceFormulary entries reference the legend to interpret PA, QL, ST, NDS and NF indicators
    Provider noteProviders should consult legend when preparing PA/exception documentation
    inv-106: NF — Formulary indicator (legend on page 6)
    NF — Not Formulary indicator'NF' appears as a formulary symbol to indicate a drug or formulation is not included on the plan's preferred drug list
    Exception processMembers may request a formulary exception for NF items per the plan's exception procedures
    Legend referenceExact definition provided on the formulary legend (page 6)
    inv-107: PA / QL / ST — PA = prior authorization; QL = quantity limit; ST = step therapy
    PA / QL / ST — AbbreviationsPA = prior authorization; QL = quantity limit; ST = step therapy — abbreviations used in the Requirements/Limits column
    Operational meaningExact operational rules for these controls are defined in plan policies and the formulary legend
    Where appliedThese flags appear next to product names and modify coverage requirements
    inv-108: NF — Non-formulary indicator appears in the table
    NF — Non‑Formulary presenceNF appears within product rows to flag non‑formulary status in the listing; users should consult page 6 legend for details
    CoverageNF usually denotes the item is not covered under standard formulary benefits
    Exception optionMembers can request a formulary exception when medication is NF
    inv-109: ST — Step Therapy — the product requires meeting step therapy rules
    ST — Step Therapy indicator'ST' denotes step therapy requirements apply where shown (member may need to try specified preferred drugs first)
    ExamplesXCOPRI therapy packs, EXXUA and other branded products are shown with ST in the Requirements/Limits column
    Provider actionWhen ST is present, providers must document failure/intolerance of preferred agents per plan step policy
    inv-110: PA — Prior Authorization — the product requires prior authorization before coverage
    PA — Prior Authorization required before coverageProducts marked 'PA' in the formulary require prior authorization before the plan will provide coverage
    ExamplesMultiple specialty agents (e.g., PRALUENT, REPATHA, LYBALVI) display PA flags in the listing
    Submit documentationPA submissions should include clinical rationale and relevant medical records per plan instructions
    inv-111: QL — Quantity Limit — specifies maximum units allowed in a time period (e.g., EA per 30 days)
    QL — Quantity Limit definitionQL specifies the maximum units allowed in a time period (e.g., 30 EA per 30 days) as shown in Requirements/Limits
    ExamplesCommon examples include QL (30 EA per 30 days), QL (60 EA per 30 days), and ML-based limits for injectables/solutions
    EnforcementPharmacy claims are adjudicated against listed QLs; overrides require PA/exception
    inv-112: NDS / NF — NDS indicates non-standard supply; NF indicates non-formulary
    NDS / NF — Legend symbolsFormulary uses NDS (non‑standard supply) and NF (non‑formulary) annotations; see page 6 legend for full definitions
    Where usedNDS/NF may appear with PA/QL annotations to indicate special supply or non‑formulary handling for particular strengths/presentations
    Provider noteCheck legend and plan policy when these symbols appear to determine coverage rules
    inv-113: PA / QL / ST — PA = prior authorization required; QL = quantity limit (with specifics like '60 EA per 30 days'); ST = step therapy
    QL examples — 60 EA per 30 daysFormulary includes many QL examples; 60 EA per 30 days is frequently used for oral tablet presentations
    Where shownQL values are displayed in the Requirements/Limits column adjacent to each product entry
    ReferenceConsult product row for the exact QL period and unit type

    Step Therapy Rules and Affected Products

    RequirementDescription
    Members must try specified preferred drugs first
    If a preferred drug (Step 1) does not work, the plan will cover the alternate drug (subsequent step) after failure of the preferred agent
    Entry attributeObservation
    Quantity limits (QL)
    Formulary tier designations (numeric tiers and NF)
    Explicit multi‑step sequences not listed in these chunks; only tier/QL annotations
    FindingSupportive example
    Some agents show tier and Requirements/Limits changes that may reflect claims-level edits
    Example: lopinavir‑ritonavir entries show PA and changed QL values across formulations (PA; QL 360 EA per 30 days = QL 240 EA per 30 days)
    StatementImplication
    No explicit step therapy sequences are provided in these fragments
    Formulary lines include tier, PA, and QL flags only — step algorithms not detailed here
    ObservationExample
    Some oral tablet products are placed on lower tiers indicating preferred status
    Example: multiple statin/tablet strengths and certain atorvastatin/ezetimibe entries show lower tier placement in the listing
    FindingNotes
    Some vasodilators and other agents are marked 'PA'
    Example: dipyridamole listed with PA; isosorbide and other vasodilator entries appear with tier assignments but PA noted where indicated
    FindingExample
    Certain strengths/forms of armodafinil require prior authorization
    Example: armodafinil 150/200/250 mg entries show 'PA; QL (30 EA per 30 days)' while 50 mg shows PA; QL (60 EA per 30 days)
    ProductST flag / note
    XCOPRI therapy packs and tablets
    Designated 'ST' in formulary entries indicating step therapy requirements apply
    ProductST flag / note
    SAVELLA oral tablets and titration packs
    Marked 'ST' (titration packs also show ST and QL where indicated) — step therapy edits apply
    ProductST designation
    EXXUA titration pack and extended‑release presentations
    Listed with 'ST' (and QL 30 EA per 30 days for titration pack) indicating step therapy applies
    ProductsST indication
    FANAPT oral tablet and titration packs
    FETZIMA oral capsule and titration packs; SECUADO transdermal — entries labeled 'ST' where indicated
    ProductFormulary flag
    SANCUSO transdermal patch (scopolamine)
    Listed as 'ST; QL (4 EA per 28 days)' indicating step therapy requirement applies

    Quantity Limits by Product (Selected Examples)

    inv-126: Glipizide ER 10mg — 60
    Coverage check — plan rules applyDrugs are covered when on the AmeriHealth Medicare PPO formulary and when any specified Requirements/Limits (PA, QL, ST) are met
    Temporary supply/transition fillsPlan may provide temporary supplies (e.g., 30‑day) during transitions; consult formulary transition rules for specifics
    How to confirmConsult the product line entry in the formulary to identify any PA, QL, ST or NF indicators that modify coverage
    inv-127: Opioid medications — 30
    Opioid supply limitOpioid medications are limited to a 30‑day supply for retail and mail order (31 days for long‑term care)
    Refill ruleOptumRx Home Delivery requires 90% of opioid medication be used before refill; other pharmacies may have additional limits
    Formulary noteOpioid QL and NDS rules are indicated in the Requirements/Limits column for specific opioid products
    inv-128: fidaxomicin — 60
    Fidaxomicin — QL 60Fidaxomicin oral tablet listed with QL (60 EA per 30 days)
    ContextAppears in anti‑infective section with QL 60 EA per 30 days applied consistently across several antibacterial entries
    Provider noteRefer to product row for any accompanying PA/NF flags when dispensing
    inv-129: linezolid oral tablet — 56
    Linezolid oral tablet — QL 56 per 28 daysLinezolid oral tablet is listed with QL (56 EA per 28 days)
    Related formsLinezolid oral suspension and other presentations may have differing QLs; consult product lines for exact limits
    ReferenceSee formulary entry specifying QL period (28 days) for this product
    inv-130: Multiple antiviral agents listed — QL examples: 30 EA/30 days, 168 EA/365 days, 84 EA/365 days, 360 EA/30 days
    Antiviral QLs — multiple examplesAntiviral agents show diverse QLs: QL (30 EA per 30 days), QL (168 EA per 365 days), QL (84 EA per 365 days), QL (360 EA per 30 days)
    Product examplesEntries include BIKTARVY, EPCLUSA, MAVYRET, lopinavir‑ritonavir with the noted QLs and sometimes PA flags
    Apply per formulationExact QL depends on specific product presentation (packets, tablets, therapy packs); consult the product row
    inv-131: PAXLOVID therapy packs — QL examples: 20 EA per 5 days, 11 EA per 5 days, 30 EA per 5 days
    PAXLOVID therapy packs — pack‑specific QLsPAXLOVID therapy pack entries show QL examples such as QL (20 EA per 5 days), QL (11 EA per 5 days), and QL (30 EA per 5 days)
    Course‑based limitsTherapy pack QLs are specified per treatment course (5‑day periods) rather than monthly EA limits
    Provider noteConfirm the therapy pack presentation and corresponding QL when prescribing or dispensing PAXLOVID
    inv-132: REYATAZ oral capsule — QL (360 EA per 30 days)
    REYATAZ — QL 360 EA per 30 daysREYATAZ oral capsule entries are shown with PA; QL (360 EA per 30 days)
    PA presencePA may accompany high QL values for certain antiretroviral agents; check product row for PA flag
    Dispensing noteLarge monthly EA QLs apply to some antiretroviral products due to packet/therapy presentations
    inv-133: STRIBILD oral tablet — QL (30 EA per 30 days)
    STRIBILD — QL 30 EA per 30 daysSTRIBILD oral tablet entry shows QL (30 EA per 30 days)
    Formulation noteCombination antiretroviral tablets commonly use monthly EA QLs; confirm per product row
    PA/NF checkSome antiviral products also include PA or NF flags depending on strength/formulation
    inv-134: SUNLENCA therapy pack 4 x 300 mg — QL (4 EA per 28 days)
    SUNLENCA therapy pack — QL 4 EA per 28 daysSUNLENCA therapy pack 4 x 300 mg is listed with QL (4 EA per 28 days)
    Pack variationsOther SUNLENCA therapy pack presentations have different QLs (e.g., 5 EA per 28 days for 5×300 mg pack)
    Provider actionConfirm therapy pack size and corresponding QL when prescribing/dispensing
    inv-135: BOSULIF oral tablet 100 mg — QL (180 EA per 30 days)
    BOSULIF 100 mg — QL 180 EA per 30 daysBOSULIF oral tablet 100 mg entry shows QL (180 EA per 30 days)
    Alternate strengthsOther BOSULIF strengths may show different QLs or PA flags (see product lines)
    ContextHigher tablet QLs are used for chronic oncology oral agents as indicated
    inv-136: KISQALI therapy packs — QL (63 EA per 28 days)
    KISQALI therapy packs — QL 63 EA per 28 daysKISQALI therapy pack presentations show QL (63 EA per 28 days) and require PA where indicated
    PA flagKISQALI entries include PA in the Requirements/Limits column in the formulary extract
    Pack dosingTherapy pack QLs reflect pack dosing schedules; confirm pack type when prescribing
    inv-137: LONSURF oral tablet — QL (240 EA per 30 days)
    LONSURF — QL 240 EA per 30 daysLONSURF oral tablet entry shows QL (240 EA per 30 days) with PA indicated for some presentations
    PA/QL combinationOncology oral agents often combine PA and high EA QLs based on therapy pack sizes
    Provider noteCheck product row for both PA and QL when initiating therapy
    inv-138: LENVIMA therapy packs (various mg) — 30-90 EA
    LENVIMA therapy packs — 30–90 EALENVIMA therapy pack entries show QL ranges from 30 to 90 EA depending on daily dose and pack presentation
    PA indicatedLENVIMA therapy packs commonly include PA with QL specified per pack/dose
    Check dosingExact QL depends on the listed daily dose (4 mg up to 24 mg presentations) — consult product line
    inv-139: MEKINIST oral solution — QL (1200 ML)
    MEKINIST oral solution — QL 1200 ML per 30 daysMEKINIST oral solution reconstituted is listed with QL (1200 ML per 30 days)
    PA presentMEKINIST entries show PA along with the ML‑based QL for solution presentations
    Usage guidanceLarge ML QLs reflect solution dosing for oncology agents; verify product presentation when dispensing
    inv-140: VENCLEXTA STARTING PACK — QL (84 EA)
    VENCLEXTA STARTING PACK — QL 84 EA per 365 daysVENCLEXTA starting pack therapy packaging is listed with QL (84 EA per 365 days)
    PA requirementPA is shown for VENCLEXTA starting pack in the formulary extract
    Pack‑based QLStarter packs often have year‑based QLs reflecting course length; check product row for exact period
    inv-141: ABRYSVO — 1 EA; inv-142: AREXVY — 1 EA
    ABRYSVO — QL 1 EA per 252 daysABRYSVO intramuscular solution reconstituted is listed with QL (1 EA per 252 days)
    AREXVY — QL 1 EA per 999 daysAREXVY intramuscular suspension is shown with QL (1 EA per 999 days) in vaccine section
    Vaccine QLsVaccine products frequently use long‑period QLs (per 252 days, per 999 days) tailored to dosing schedules
    inv-143: MRESVIA IM prefilled syringe — 0.5 ML
    MRESVIA prefilled syringe — QL 0.5 ML per 999 daysMRESVIA intramuscular suspension prefilled syringe is listed with QL (0.5 ML per 999 days)
    Vaccine schedulingUnique QL periods reflect infrequent dosing schedules for certain IM biologics
    Legend referenceConsult formulary legend for interpretation of extended QL periods
    inv-144: INCRUSE ELLIPTA 62.5 MCG/ACT — 30 EA; inv-145: SPIRIVA HANDIHALER — 30 EA
    INCRUSE ELLIPTA — QL 30 EA per 30 daysINCRUSE ELLIPTA inhalation aerosol powder 62.5 MCG/ACT entry shows QL (30 EA per 30 days)
    SPIRIVA HANDIHALER — QL 30 EA per 30 daysSPIRIVA HandiHaler inhalation capsule entry shows QL (30 EA per 30 days)
    Inhaled QLsInhaled bronchodilator and combination inhaler presentations use EA or GM units with specified monthly QLs
    inv-146: fluticasone-salmeterol inhalation aerosol powder — 60 EA
    fluticasone‑salmeterol — QL 60 EA per 30 daysBreath‑activated fluticasone‑salmeterol inhalation powder entries show QL (60 EA per 30 days)
    Alternate form limitsSome breath‑activated strengths list QL (1 EA per 30 days) for specific actuator/presentation types
    Provider noteConfirm exact strength/presentation as QL may vary by actuation strength and form
    inv-147: varenicline tartrate (starter and continuing packs) — 504 EA
    Varenicline tartrate packs — QL 504 EA per 365 daysVarenicline tartrate starter and continuing packs are listed with QL (504 EA per 365 days)
    Smoking cessation categoryQL reflects combined starter/continuing pack unit counts over a 365‑day period
    Provider actionCheck pack type (starter vs continuing) when prescribing due to combined annual QL
    inv-148: COMBIVENT RESPIMAT — 8
    COMBIVENT RESPIMAT — QL 8 GM per 30 daysCOMBIVENT RESPIMAT inhalation aerosol solution is shown with QL (8 GM per 30 days)
    Unit type noteSome inhalation nebulizer products use GM (grams) rather than EA for quantity limits
    Formulary enforcementPharmacies should apply the GM‑based QL when adjudicating claims for these solutions
    inv-149: fluticasone‑salmeterol (breath-activated) — 60; inv-150: PROAIR RESPICLICK — 2
    PROAIR RESPICLICK — QL 2 EA per 30 daysPROAIR RESPICLICK breath‑activated inhaler entry shows QL (2 EA per 30 days)
    Common inhaler QLSome commonly used rescue inhalers have low monthly EA QLs (e.g., 2 EA per 30 days) depending on presentation
    Check strength/presentationDifferent actuator types and strengths may have different QLs — confirm product row